New Quantum Water Model helps find stable ss DNA conformation in solution

ss DNA Molecular dynamics trajectory using the latest Quantum force field helps to find a perfectly stable conformation of the biomolecule in solution. The outcome of the simulation is very reasonable, given the fact that ss DNA (such as telomers) tend indeed to form such loops (see the Figure on the right). The Figure shows the structure of a DNA quadruplex formed by telomere repeats. The conformation of the DNA backbone diverges significantly from the typical helical structure

Quantum LogP module (part of q-Mol package) has been benchmarked by vcclab.org

Quantum LogP module (part of q-Mol package) has been reviewed by R. Mannhold et al. (vcclab.org) in "Calculation of Molecular Lipophilicity: State-of-the-Art and Comparison of Log P Methods on More Than 96,000 Compounds". From the manuscript:

"Quantum LogP, developed by Quantum Pharmaceuticals, uses another quantum-chemical model to calculate the solvation energy. Like in COSMO-RS, the authors do not explicitly consider water molecules but use a continuum solvation model. However, while the COSMO-RS model simplifies solvation to interaction of molecular surfaces, the new vector-field model of polar liquids accounts for short-range (H-bond formation) and long-range dipole–dipole interactions of target and solute molecules Quantum LogP calculated log P for over 900 molecules with an RMSE of 0.7 and R2 of 0.94".

Computer aided drug design video from Quantum Pharma

Molecular modelling software of Quantum Pharmaceuticals is used to dock small molecule to active site of target protein. The molecular docking on flexible protein is explored. The Quantum docking software is available for free use at LeadFinding.com, the online hit-to-lead optimization service to filter and profile chemical compounds in chemical database of ChemDiv - organic chemistry supplier.

q-hERG: QUANTUM's innovative approach to hERG binding calculations is finally released

QUANTUM hERG (q-hERG) screening assays is a unique and innovative computational approach, which allows you to predict from a molecule structures of compounds their inhibition constants (IC50) for hERG channels.

q-hEARG features:

• Output is pIC50 values (-logIC50) for the molecules. The accuracy of prediction is 1.1 pIC50 units;
• No training sets or QSAR methods applied;
• hERG inhibition prediction is made by docking of compound on Quantum Pharmaceuticals’ Proprietary Flexible 3D structure of hERG;
• Docking is based on quantum and molecular physics (see Quantum Science Core for an overview);
• Average correlation has RMSD=1.18 pIC50 unit, and correlation coefficient = 0.82;
• Easy to use user interface, no special hardware requirements, both Linux/Windows supported;
• You can also request services based on QUANTUM hERG Screening Assays.

q-hERG is an independent software module, sharing the user interface and basic usage concepts with our q-ADME: ADME/PK properties prediction software, q-Mol: physico-chemical properties calculator, and q-Tox: toxicological profiling software. More information, including q-hERG product booklet can be obtained from the Quantum Pharmaceuticals products site.

Obtaining Q-Albumin software:

Please review your licensing options, add Q-Albumin: QUANTUM Albumin Binding Prediction Software to your shopping card and checkout to get the download links.

Licensing Options: One Month License $50,00 One Year License $100,00

And continue to CHECK OUT

EMD Serono, Inc licensed Quantum Pharmaceuticals’ drug discovery technology.

Moscow, 10 December, 2007

EMD Serono, Inc entered license agreement with Quantum Pharmaceuticals to get an access to Quantum Pharmaceuticals’ small molecule hit identification computational platform and apply it in in-house research.

The Quantum Pharmaceuticals’ industry leading computational drug design technologies is based on applying quantum, molecular and statistical physics in molecular modeling and was successfully applied in different drug discovery projects. The initial term of the agreement is one year. The financial terms of the agreement were not disclosed.

Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

EMD Serono, Inc. and Merck Serono S.A. are affiliates of Merck KGaA, Darmstadt, Germany, with over 16,000 employees worldwide and a strong presence on all continents.

QUANTUM and albumin binding calculations: the role of protein flexibility

Drug distribution within the body is determined mainly by free (unbound) concentration of drug in circulating plasma. The unbound fraction, in turn, depends on drug absorption by plasma proteins. Human Serum Albumin (HSA) is the most abundant blood plasma protein and is produced in the liver.

Binding of a compound to HSA results in an increased solubility in plasma, decreased toxicity, and /or protection against oxydation of the bound ligand. Binding can also have a significant impact on the pharmacokinetics of drugs, e.g. prolonging in vivo half life of the therapeutic agent. However too strong binding prevents drug release in tissues. That is why HSA binding information is one of the key characteristics of a compound determining its ADME properties. Successful in silico calculation of HSA binding could provide a structural basis of drug derivatives with altered HSA-binding properties.

HSA has at least two main drug binding sites characterized as Sudlow site I and Sudlow site II, which bind a number of drugs selectively. Site I, also known as the warfarin binding site, is formed by a pocket in subdomain IIA of HSA. Site II is located in subdomain IIIA and is known as the benzodiazepine binding site. Ibuprofen and diazepam are selectively bind to site II. Multiple active sites make HSA a complicated target for structure-based modeling.

The ligands with known HSA binding affinities were taken from and prepared with a set of built in QUANTUM molecular preparation and processing tools. Acenocoumarol, Acetylsalicilic_acid, Azapropazone, Benzylpenicillin, Benzylthiouracil, Bilirubin, Canrenoate, Carbamazepine, Carbenicillin, Chlorpropamide, Diphenylhydantoin, Furosemide, Indomethacin, Methyl_p-hydroxybenzoate, N-acetyl-L-tryptophan, Oxyphenbutazone, Phenobarbital, phenyl_salicylate, Phenylbutazone, Piretanide, Propyl_p-hydroxybenzoate, Quercetin, Salicylate, Sodium_benzoate, Spironolactone, Sulfadimethoxine, Sulfamethizole, Sulfathiazole, sulfisoxazole, Tenoxicam, Tolbutamide, Warfarin, Carprofen, Chlofibrate, Iopanoate, L-tryptophan were docked on to both of the sites. Three different structures – 2BXH, 2BXF and 2BXG were taken for docking. 2BXH was used for docking to the first binding site, 2BXF and 2BXG have different structures of the binding site II and we decided to use both structures for docking. Docking grid 20x20x20A were centered around a central ligand atom in appropriate binding site.

The results of the docking runs are summarized on the Figure. Both binding sites show considerable flexibility, molecular dynamics and the binding free energy calculations with flexible protein (large red points) lead to remarkable improvement of the predicted values of HSA binding affinities with respect to experiment (smaller blue points represent the results of docking on a rigid protein model). Since QUANTUM model does not have training parameters the presented correlation proves QUANTUM abilities to predict HSA binding constants of druglike compounds to both of the active sites.